Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis.

Patient Prefer Adherence · 2017 · PMC5481282 · PMID 28670113

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Among patients ≤48 years old, PCS scores increased significantly from baseline to years 2 and 3 (adjusted CFB: 3.15 [ P <0.05] and 3.42 [ P <0.01], respectively), whereas CFBs did not reach statistical significance for patients aged >48 years.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.